Repligen (RGEN) Bank of America Global Healthcare Conference 2026 summary

Financial performance and outlook

• Achieved a strong first quarter, exceeding expectations in both revenue and earnings, leading to increased confidence in full-year guidance and a raised EPS outlook.

• Organic growth for Q1 was 11%, with similar expectations for Q2, aligning with annual guidance and not requiring acceleration in the second half.

• Margin expansion initiatives are underway, including the launch of a Transformation Office to drive sustainable and accelerated improvements, targeting about one point of margin expansion by the end of 2027.

• Announced the sale of a loss-making segment and an OEM partnership in China to enhance local competitiveness and growth.

Segment and product performance

• Protein and chromatography segments experienced strong growth, with analytics also performing well, driven by new product launches and upgrade cycles.

• Filtration grew at mid-single digits, with some headwinds in ATF due to customer inventory management, expected to rebound next year.

• Equipment growth was led by analytics (up 50% in Q1, 40% organic) and mixers, while traditional downstream filtration systems remained flat due to delayed customer decisions.

• New generation analytics devices (SoloVPE PLUS) contributed to strong performance, with an upgrade cycle expected to provide tailwinds for 18–24 months.

Market and customer dynamics

• Growth is primarily driven by monoclonal antibodies (mAbs), while new modalities, especially gene therapy, remain dilutive due to a specific customer headwind, expected to ease next year.

• Cell therapy showed encouraging growth, and gene therapy (excluding the headwind) also grew in Q1.

• Emerging biotech funding has improved, with four consecutive quarters of growth, but revenue contribution remains below historical levels as spending lags funding.

• China is rebounding, with new leadership and an OEM partnership supporting local manufacturing and future expansion plans.